Denis T. (Scot) Flynn, PA-C

Office:
Community Clinical Research, Inc
8334 Cross Park Dr.
Austin, TX 78754
Phone: 512-323-2622
Fax: 512-323-2625
scot.flynn@communityclinical.com

Licensure & Certification
Physician Assistant, State of Texas #PA07544
Controlled Substance Registration # CSP.0044781
Certification, NCCPA Certification # 1080205
DEA #MF1865077
DPS #G0197028
NPI #1609-028-083

Education & Training
Bachelor of Science in Physician Assistant Studies, 2006-2008
Long Island University, Brooklyn Campus, New York
~Elected, Class Representative, 2006-2008
~Elected, Vice President, SAAPA, 2006-2008

El Paso Community College, El Paso, Texas
~ Selected, Peer tutor in Statistics, study group leader 2005

University of Texas at El Paso, El Paso, Texas
~ Member, Medical Professions Institute, Alpha Epsilon Delta 2005-2006

Post-baccalaureate pre-medical coursework, 2002-2005
Southern Connecticut State University, New Haven, Connecticut
~ Member, Chemistry Club, 2003-2004
~ Selected, Peer Tutor in Organic and General Chemistry Laboratory Sections 2002-2004

Bachelor of Arts in Psychology, 1997-2000
University of San Diego, San Diego, California
~ Vice President, Psychology Club 1999 - 2000
~ Team Member, Tijuana Outreach Project, 1998 - 2000
~ Selected, Peer Tutor in English, History, Social Studies 2000

Bilingual in English and Spanish

3/8/14

Professional Experience

Community Clinical Research, Austin, Texas July 2011 – Present
Sub Investigator/Rater

- Data collection, research for early phase clinical trials of medications for the treatment of schizophrenia, bipolar disorder, depression and other psychiatric illnesses.
- Provide ongoing treatment and medication management for out-patients.
- Supervising Physician Dr. David Brown, MD

Austin Recovery Center, Buda, Texas May 2013- Present
Psychiatric/Addiction Medicine Physician Assistant

- Manage alcohol and substance detox protocols for patients withdrawing from EtOH, opiates, benzodiazepines, meth/amphetamines, cocaine etc.
- History and physical examinations for admitted patients.
- Medical management for admitted patients
- Consultation-liason service via videoconference or telepsychiatry.
- Supervising Physician Dr. Marilyn Vache, MD

Embracia Health, Austin, Texas September 2016-Present
Psychiatric Physician Assistant

- Perform Psychiatric/Mental Health evaluations on all new out-patients
- Diagnose, treat, provide treatment plans through medication management
- Supervising Physician Dr. Hachem Dadouch, MD

Cross Creek Hospital, Austin, Texas March 2015- May 2016
Psychiatric Physician Assistant

- Manage alcohol and substance detox protocols for patients withdrawing from EtOH, opiates, benzodiazepines, meth/amphetamines, cocaine etc.
- History and physical examinations for admitted patients.
- Acute psychiatric management for admitted patients
- Daily follow-up care and medication management for admitted patients

Bridgeport Hospital, Bridgeport, Connecticut August 2008 – July 2011
Physician Assistant- Department of Psychiatry

- Serve on both acute adult inpatient and geriatric units, providing quality Psychiatric care in collaboration with multidisciplinary team, including, but not limited to emergency psychiatric management, stabilization of psychotic, suicidal, homicidal, and dual diagnosis patients.
- Provide Psychiatric consultation/liaison services to various departments throughout the hospital.
- Manage medication regimens and treatment plans for admitted patients and daily follow up.
- Precept medical and PA students rotating through the department. Provide accurate clinical tracking of patient symptomatology through scales such as CGI, MADRS, PANSS, BPRS, YMRS as well as various mood charts (also used daily as tools for teaching students how to assess psychiatric patients)

3/6/17

Industrial Medical Center, Bridgeport, CT June 2010 – July 2011
Physician Assistant-PRN

- History and Physical exams for pre-employment health screenings
- Assess, diagnose and treat work related injuries
- Provide quality care for ill hospital employees
- Evaluate for worker's compensation

La Carpio Community Clinic, San Jose, Costa Rica February 2009
Physician Assistant Volunteer- Family/Community Medicine

- Provide quality care to underserved/undocumented Nicaraguan community
- Travel for several weeks throughout the year, working with Family Medicine Physician
- History and Physical examinations, health education, urgent care, outsource referrals

Providence Memorial Hospital, El Paso, Texas 2005–2006
Emergency Medical Technician

- Maintained hospital and decontamination supplies, lifting/moving patients, performing CPR, basic trauma life support.
- Collaborated closely with multidisciplinary team members, working alongside physicians, physician assistants, nurses, respiratory therapists and fellow EMT's.
- Assisted in procedures such as IV/arterial line access, suturing, conscious sedations, lumbar punctures, intubations, chest tube insertions, blood transfusions, as well as several other critical procedures.
- Primary duties included, but not limited to, continuously monitoring patient vital signs, phlebotomy, wound care management, collecting sample specimens, removing sutures, inserting foley catheters, recording ECG's, and providing basic life support and care/comfort as necessary.

Texas Tech University Health Sciences Center, El Paso, Texas 2004
Student Preceptorship in Border Medicine

- Performed history/physical examinations, phlebotomy, vaccinations, minor procedures.
- Gained exposure to a wide range of family/community medicine in the underserved areas of east El Paso, Texas.
- Attended hospital rounds and morning reports with physicians. Provided treatment information and comfort to patients and families.

Universidad Autonoma De Guadalajara School of Medicine, 2003
Medicina en la Comunidad, Guadalajara, Mexico
Rotation in Community/Family Medicine (note: not a matriculated student at the School of Medicine)

- Consulted with patients, follow-up cases, performed history/physical examinations, attended to house calls and clinical cases.

3/8/14

- Improved medical-Spanish fluency, studied Public Health aspects, attended seminars on infectious disease.
- Assisted in providing healthcare to underserved areas of the city of Guadalajara.

Shire-Richwood Pharmaceuticals, San Diego, California 2001
Research Coordinator/ Rater

- Medication Trials through San Diego Developmental Specialists, A Randomized, Double-Blind Placebo, Controlled, Parallel-Group Study of SLI381(Adderall XR) in Children With Attention-Deficit Hyperactivity Disorder. Biederman, J, Lopez, F, Boellner, S, Chandler,

San Diego Developmental Specialists, San Diego, California 2000 – 2002
New Patient/Intake Coordinator

- Assisted Developmental/Behavioral Pediatricians in comprehensive neuro-developmental assessments and treatment plans for children, adolescents, and families struggling with learning, developmental, behavioral, and mood disorders.
- Gathered psychosocial histories and presented findings at weekly team meetings.
- Administered continuous performance tests of attention (TOVA) and recorded observations.
- Scored patient rating scales, entered test results and other patient data into DOS-based outlining program, wrote psychological evaluations presented at meetings.
- Attended monthly seminars and round table discussions on psychopharmacologic research designs.

Neuropsychiatric Rating Scales Training and Certifications

- Positive and Negative Syndrome Scale (PANSS)
- Clinical Global Impressions (CGI)
- Montgomery-Asberg Depression Rating Scale (MADRS)
- Abnormal Involuntary Movement Scale (AIMS)
- Extrapyramidal Symptom Rating Scale (ESRS)
- Structured Clinical Interview for DSM-IV-TR (SCID)
- MINI International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorders (MINI)
- Young Mania Rating Scale (YMRS)
- Columbia Suicide Severity Rating Scale (C-SSRS)
- Simpson Angus Scale (SAS)
- Barnes Akathisia Rating Scale (BARS)
- Hamilton Depression Rating Scale (HAM-D)
- Hamilton Anxiety Rating Scale (HAM-A)
- Personal and Social Performance Scale (PSP)
- Negative Symptoms Assessment Scale (NSA)
- ADAS-cog
- Brief Psychiatric Rating Scale (BPRS)
- Calgary Depression Scale for Schizophrenia (CDSS)
- Global Assessment of Functioning (GAF)
- Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30)
- Clinical Opiate Withdrawal Scale (COWS)

3/9/18

- CIWA-A/CIWA-B (Clinical Institute Withdrawal Assessment EtOH and Benzodiazepines)
- CAPS-5 (Clincian Administered PTSD Scale for DSM-5)

Leadership Experience

Tenet Healthcare Corporation, Nacogdoches, Texas 2005
Disaster Medical Assistance, Hurricane Katrina Relief, Nacogdoches Medical Center

- Chosen among 35 Emergency Room Technicians to initiate and direct relief effort in Emergency Department of Nacogdoches Medical Center in response to patient overflow.
- Received personal letter of recognition in response to efforts from Thomas Casaday, CEO, Providence Memorial Hospital.

- Performed basic trauma life support and followed typical emergency department protocols in treatment of transported/triaged patients from New Orleans, Louisiana.

Organizer & Member, Specialized Decontamination (DECON) Team 2005

- Participated in events and sessions providing instruction and training on decontamination procedures in biological weapons attacks.

Presentations

"Overview of Clinical Trials in Alzheimer's Disease", for San Antonio Residential Care Home Association (SARCH), San Antonio, Texas, June 12, 2015

The Brooklyn Hospital Center:
Fever of Unknown Origin- case report, Department of Pediatrics, November, 2007
Necrotizing Enterocolitis- case report, NICU, November 2007

Parker Jewish Institute:
Management of CHF in the Elderly Patient, Long Term Care Facility, January 2008

Soccorro Community Retirement Center:
Depression: Signs and Symptoms in the Geriatric Population. El Paso, Texas. July 2004
Case Report: Anemia in the Elderly Patient. El Paso, Texas. July 2004.

Participation in Clinical Research

6981-CL-0004: A Phase 1 Randomized, 2-way, Crossover Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects with Schizophrenia, Clinical Research Coordinator, sponsored by Astellas, 2018 – present.

Protocol 331-201-00083: Phase 3, A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects with Bipolar I Disorder, Principal Investigator, sponsored by Otsuka, 2017-present.

Protocol 331-201-00080: Phase 3, A Multicenter, Randomized, Double-blind Trial of Brexpiprazole versus Placebo for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder, Principal Investigator, sponsored by Otsuka, 2017-present.

3/8/19

RAP-MD-06: Phase 3, An Open-label, Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients with Major Depressive Disorder, Principal Investigator, sponsored by Naurex, Inc, an affiliate of Allergan, plc., 2017-present.

RAP-MD-04: Phase 3, A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients with Major Depressive Disorder, Principal Investigator, sponsored by Naurex, Inc, an affiliate of Allergan, plc., 2017-present.

RAP-MD-02: Phase 3, A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder, Principal Investigator, sponsored by Naurex, Inc, an affiliate of Allergan, plc., 2017-present.

ALK3831-A109: A Phase 1, Study to Evaluate the Effect of Multiple Doses of ALKS 3831 on QTc Interval in Subjects with Schizophrenia, Principal Investigator, sponsored by Alkermes, 2017-present.

031-201-00104: A Phase 1, Open-label, Single Ascending Dose, Parallel Arm Trial to Determine the Pharmacokinetics, Safety, and Tolerability of Aripiprazole 2 Month Intramuscular Depot Administered Gluteally in Adult Subjects with Schizophrenia, Principal Investigator, sponsored by Otsuka, 2017-present.

217-MDD-201: Phase 2, two-part (open-label followed by double-blind) study evaluating the safety, tolerability, pharmacokinetics, and efficacy of SAGE-217 in the treatment of adult subjects with moderate to severe Major Depressive Disorder, Principal Investigator, sponsored by Sage Therapeutics, 2017-present .

ROV-RISP-2016-01 Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Injections of Risperidone ISM® in Patients with Acute Exacerbation of Schizophrenia (PRISMA-3), Principal Investigator, sponsored by Laboratorios Farmacéuticos ROVI, S.A., 2017-present.

ALK3831-A308: A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder, Principal Investigator, sponsored by Alkermes, 2017-present.

ALK3831-A307 Phase 3, A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness, Principal Investigator, sponsored by Alkermes, 2017-present.

ITI-007-201 Phase 3, A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 in the Treatment of Agitation in Patients with

3/8/18

Dementia, Including Alzheimer's Disease, Principal Investigator, sponsored by Intracellular Therapies, 2016-present.

BP39207 A Phase IIb, Multicenter, Randomized, Double-blind, Parallel group, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of BASMISANIL (RO5186582) as Adjunctive Treatment in Patients with Cognitive Impairment Associated with Schizophrenia Treated with Antipsychotics, Sub-Investigator, sponsored by Roche, 2016-present.

ITI-007-303 Phase 3, An Open-Label, Multi-Center Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia , Sub-Investigator, sponsored by Intracellular Therapies, 2016-present.

HP-3070-GL-04 Phase 3, A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, In-Patient Study to Assess Efficacy and Safety of HP-3070 in Subjects Diagnosed with Schizophrenia, Sub-Investigator, sponsored by Noven, 2016-present.

TNX-CY-P301 A Phase 3, Double Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients with Military-Related PTSD, Sub-Investigator, sponsored by Tonix Pharmaceuticals, 2017-present.

16159B Phase 3, Interventional, open-label, flexible-dose, long-term safety study of Lu AF35700 in adult patients with schizophrenia, Sub-Investigator, sponsored by Lundbeck, 2017-present.

16159A Phase 3, Interventional, randomised, double-blind, active-controlled, fixed-dose study of Lu AF35700 in patients with Treatment-resistant Schizophrenia, Principal Investigator, Principal Investigator, sponsored by Lundbeck, 2017-present.

HP-3070-GL-04: Phase 3, A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, In-Patient Study to Assess Efficacy and Safety of HP-3070 in Subjects Diagnosed with Schizophrenia, Sub-Investigator, Sponsored by Noven Pharmaceuticals, 2016-present.

ITI-007-201: A Phase 3, A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 in the Treatment of Agitation in Patients with Dementia, Sub-Investigator, Sponsored by Intracellular Pharmaceuticals, 2016-present.

ITI-007-402: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 Adjunctive to Lithium or Valproate in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression), Sub-Investigator, sponsored by Intracellular, 2015-present.

ITI-007-401: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 Monotherapy in the Treatment of Patients with Major

3/8/15

Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression), Sub-Investigator, sponsored by Intracellular, 2015-present.

ALK3831-A304: A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia, Sub-Investigator, Sponsored by Alkermes, 2016-present.

ALK3831-A303: A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to Olanzapine in Adults with Schizophrenia, Sub-Investigator, sponsored by Alkermes, 2015-present.

ALK9072-B102: A Phase 1 Study of an ALKS 9072N Initiation Regimen in Adults with Schizophrenia, Sub-Investigator, sponsored by Alkermes, 2015-present.

ALK6428-A301: "A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for Use in Conjunction with Buprenorphine in Adults with Opioid Use Disorder Prior to First Dose of VIVITROL®", Sub-Investigator, sponsored by Alkermes, 2015-present.

1289.27: Phase 1c, Randomized, parallel-group, double-blind study of systemic and ocular safety, tolerability, pharmacodynamics and pharmacokinetics of 25 or 100 mg BI 409306 film-coated tablets (given orally q.d. 14 days) in patients with schizophrenia, Alzheimer's disease, and age-matched healthy volunteers Sub-Investigator,sponsored by Boehringer-Ingelheim, 2015-present.

Protocol ESKETINTRD3001: Phase 3, A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects with Treatment-resistant Depression Sub-Investigator,sponsored by Janssen Pharmaceuticals, 2015-present.

Protocol ESKETINTRD3003: Phase 3, A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression, Sub-Investigator,sponsored by Janssen Pharmaceuticals, 2015-present.

ITI-007-302: Phase 3, A Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 After 6 Weeks of Treatment in Patients With Schizophrenia, Sub-Investigator,sponsored by Intracellular, 2015-present.

TAK-063-2002: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia, Sub-Investigator,sponsored by Takeda, 2015-present.

ITI-007-009: Phase 1, An open-label cross-over study to determine the tolerability, safety and pharmacokinetics of ITI-007 administered orally as an overencapsulated tablet in patients with

3/8/19

schizophrenia and healthy geriatric volunteers, Sub-Investigator,sponsored by IntraCellular, 2015-present.

1289.6: A phase II randomised, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of four orally administrated doses of BI 409306 during a 12-week treatment period in patients with schizophrenia on stable antipsychotic treatment, Sub-Investigator,sponsored by Boehringer-Ingelheim 2014-present

ALK9072-A105: A Phase 1, Randomized, Open-label, Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects with Stable Schizophrenia, Sub-Investigator,sponsored by Alkermes, 2014-present

ITI-007-301: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia phase 3, Sub-Investigator,sponsored by IntraCellular, 2014-present

ALK9072-B101: A Phase 1, Placebo-controlled, Single Ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ALKS 9072N in Adults with Schizophrenia, Sub-Investigator,sponsored by Alkermes, 2014-present

LY03004/CT-USA-104: A Randomized, Open-Label Pharmacokinetic Study of LY03004 Compared to Risperdal Consta Following a Single Intramuscular Injection at 25mg in Stable Patients with Schizophrenia and/or Schizoaffective Disorder, Phase 1, Sub-Investigator,sponsored by Luye America Pharmaceuticals, LTD, 2014-present

RGH-MD-06: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Cariprazine (RGH-188) in the Prevention of Relapse in Patients with Schizophrenia, Phase 3, Sub-Investigator,sponsored by Forest, 2013-2014

ALK3831-401: A Phase 2, Randomized, Double-blind Study to Evaluate Efficacy, Safety, and Tolerability of ALKS 3831 in Subjects with Schizophrenia with Alcohol Use Disorder. Sub-Investigator, sponsored by Alkermes, 2014-present

LY03004/CT-USA-102: Protocol Title: A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients with Schizophrenia and/or Schizoaffective Disorder Phase 1, Sub-Investigator, sponsored by Luye America Pharmaceuticals, Ltd., 2014-present

331-13-008 An Exploratory, Multicenter, Open-label, Flexible-dose Brexpiprazole (OPC-34712) Trial in Adults With Acute Schizophrenia, Phase 3, Sub-Investigator, sponsored by Otsuka, 2014

316-13-211 – A Randomized, Controlled, Parallel Group Study to Evaluate Adherence to Treatment with and Safety and Tolerability of the Medical Information Device #1 (MIND1) System in Subjects with Bipolar 1 Disorder or Schizophrenia who are currently Treated with Oral Aripiprazole, Phase 2, Sub-Investigator, sponsored by Otsuka, 2014 3/9/18

RB-US-13-0005: An Open-Label, Long-Term Safety and Tolerability Study of RBP-7000 in the Treatment of Subjects With Schizophrenia, Phase 3, Sub-Investigator, sponsored by Reckitt Benckiser Pharmaceuticals Inc., 2014-present

RB-US-09-0010: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RBP-7000 (90 mg and 120 mg) as a Treatment in Subjects with Acute Schizophrenia Over 8 Weeks (2 Subcutaneous Doses), Phase 3, Sub-Investigator, sponsored by Reckitt Benckiser Pharmaceuticals Inc., 2014-present

MSI-CP.002: A Double-Blind, Placebo-Controlled, Randomized Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) For Patients With Major Depressive Disorder (MDD) Who Have Had An Inadequate Response to Current Antidepressant Therapy. Phase 2, Sub-Investigator, sponsored by Methylation Sciences, Inc., 2013-2014

A8241019- A 12-Week, randomized, phase 2, double-blind, parallel-group study of two dose levels of PF-02545920 compared to placebo in the adjunctive treatment of outpatients with sub-optimally controlled symptoms of schizophrenia. Phase 2, Sub-Investigator, sponsored by Pfizer, 2013-2014

14644B Interventional, open-label, flexible-dose extension study of brexpiprazole in patients with schizophrenia. Phase 3, Sub-Investigator, sponsored by Lundbeck, 2013-present.

14644A Interventional, randomized, double-blind, parallel-group, placebo-controlled, active-reference, flexible-dose study of brexpiprazole in patients with acute schizophrenia. Phase 3, Sub-Investigator, sponsored by Lundbeck, 2013-present

31-12-298, An Open-label, Multiple Dose, Safety and Tolerability Study of Aripiprazole IM Depot Administered in the Deltoid Muscle in Adult Subjects with Schizophrenia. Sub-Investigator, sponsored by Otsuka, 2013-2014

1289.18: Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 409306 film-coated tablets given orally q.d. for 14 days in patients with schizophrenia (randomized, parallel-group, double-blind, placebo-controlled study). Sub-Investigator, sponsored by Boehringer-Ingelheim, 2013-2014

ALK3831-302 A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a component of ALKS 3831, in adults with Schizophrenia treated with Olanzapine. Sub-Investigator, sponsored by Alkermes, 2013-present.

LY03004/CT-1S01, An Open-Label, Single Ascending Dose Pharmacokinetic and Safety Study of LY03004 Following Escalating Single Intramuscular Injection in Stable Patients with Schizophrenia or Schizoaffective Disorder. Sub-Investigator, sponsored by Shandong Luye Pharmacertical Co., 2013-2014

31-12-293, A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the

3/8/18

Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents with Tourette's Disorder, Sub-Investigator, sponsored by Otsuka, 2013-2014

31-08-252, A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Bipolar I Disorder. Sub-Investigator, sponsored by Otsuka, 2013-present

ALK9072-003, A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects with Acute Exacerbation of Schizophrenia. Sub-Investigator, sponsored by Alkermes, 2012-2014

ALK9072-003EXT, A Phase 3, Multicenter, Extension of Study ALK9072-003 to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects with Stable Schizophrenia. Sub-Investigator, sponsored by Alkermes, 2012-2014

ALK9072-101, A Phase 1, Randomized, Open Label, Single-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ALKS 9072 Following Administration to the Deltoid or Gluteal Muscle in Subjects with Chronic Stable Schizophrenia. Sub-Investigator, sponsored by Alkermes, 2012-2013

31-12-291, A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults with Schizophrenia. Sub-Investigator, sponsored by Otsuka, 2012-2013

31-12-297, A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients with Schizophrenia. Sub-Investigator, sponsored by Otsuka, 2012-2013

D1050238: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of Lurasidone for the Maintenance Treatment of Subjects with Schizophrenia. Sub-Investigator, sponsored by Sunovion, 2012-2014

D1050307 : A 12-Week, Multicenter, Open-label Extension Study in Subjects with Schizophrenia. Sub-Investigator, sponsored by Sunovion, 2012-2014

331-10-231: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia. Sub-Investigator, sponsored by Otsuka 2012-2014

331-10-237: A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults with Schizophrenia. Sub-Investigator, sponsored by Otsuka, 2012-present

331-10-242 A Parallel-arm, Double-blind, Placebo and Positive Controlled Multiple Oral Dose Administration Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects with Schizophrenia or Schizoaffective Disorder. Sub-Investigator, sponsored by Otsuka, 2012

3/9/15

RGH-MD-75 A Double-Blind, Placebo- Controlled, Study of Cariprazine (RGH-188) As Adjunctive Therapy In Major Depressive Disorder. Sub-Investigator, sponsored by Forest, 2012

H8Y-MC-HBBN A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Safety and Efficacy Study of LY2140023 in Patients with DSM-IV-TR Schizophrenia. Sub-Investigator, sponsored by Eli Lilly and Company, 2011-2012

TAK-375SL_201 A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1 mg, 0.4 mg, and 0.8 mg in the Treatment of Acute Depressive Episodes Associated with Bipolar I Disorder in Adult Patients who are on Lithium and/or Valproate. Sub-Investigator, sponsored by Takeda 2011-2014

TAK-375SL_203 A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of once a day,TAK-375 SL 0.1 mg, 0.4 mg, and 0.8 mg As An Adjunctive Therapy To Treatment-As-Usual In The Maintenance Treatment of Bipolar I Disorder in Adult Patients. Sub-Investigator, sponsored by Takeda 2011-2014

P05691. A Phase 3b, Multicenter, Double-Blind, Fixed-Dose, Parallel-Group, Three Week Placebo Controlled Trial Evaluating the Safety and Efficacy of Asenapine in Subjects With Bipolar 1 Disorder Experiencing an Acute Manic or Mixed Episode [formerly 041044]). Sub-Investigator, sponsored by SPRI-Merck, 2012-2014

P05692 A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed with Bipolar 1 Disorder who Completed Protocol P05691 (formerly 041044) (Phase 3B, formerly 041045]). Sub-Investigator, sponsored by SPRI-Merck, 2012-present

ITI-007-005: A randomized, double-blind, placebo-controlled, multi-center study to assess the antipsychotic efficacy of ITI-007 in patients with schizophrenia Sub-Investigator, sponsored by IntraCellular, 2012-2014

ALK5461-202 A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate ALKS 5461 in Subjects with Major Depressive Disorder and Inadequate Response to Antidepressant Therapy. Sub-Investigator, sponsored by Alkermes 2012-2013

31-11-289 An Open-label, Safety and Tolerability Trial of Aripiprazole IM Depot Initiation In Adult Subjects with Schizophrenia Stabilized on Atypical Oral Antipsychotics other than Aripiprazole. Sub-Investigator, sponsored by Otsuka, 2012

31-11-290 – An Open-label, Randomized, Parallel Arm, Bioavailability Trial of Aripiprazole IM Depot Administered in the Deltoid or Gluteal Muscle in Adult Subjects With Schizophrenia, Sub-Investigator, sponsored by Otsuka, 2012-2013

H8Y-MC-HBCG A Placebo- and Positive-Controlled Study of the Electrophysiological Effects

3/8/14

on the QT Interval after a Supratherapeutic Dose of LY2140023 in Subjects with Schizophrenia. Sub-Investigator, sponsored by Eli Lilly and Company, 2012-2013

P05688 A Multicenter, Randomized, Double-Blind, Fixed Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared with Placebo Using Olanzapine as an Active Control in Subjects With an Acute Exacerbation of Schizophrenia (Phase 3B, Protocol P05688 (formerly 041038). Sub-Investigator, sponsored by SPRI-Merck, 2012-present

P05689 A Multicenter, Double-Blind, Fixed Dose, Lont-Term Extension Trial of the Safety of Asenapine using Olanzapine as an Active Control in Subjects Diagnosed with Schizophrenia who Completed Protocol P05688 (formerly 041038) (Phase 3B, Protocol P05689 (formerly 041039). Sub-Investigator, sponsored by SPRI-Merck, 2012-present

R092670-PSY-3012; Phase 3 A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subjects with Schizophrenia. Sub-Investigator, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., 2012-2014

CNS162-006 A Multicenter, Randomized, Double-blind, Active-Controlled Study of the Efficacy and Safety of Flexibly-Dosed BMS-820836 in Patients with Treatment Resistant Major Depression. Sub-Investigator, sponsored by Bristol-Myers Squibb, 2011-2012

CN162-010: A Multicenter, Double-Blind, 58-week Rollover Study to assess the Safety and Tolerability of BMS-820836 in Patients with Treatment Resistant Major Depression. Sub-Investigator, sponsored by Bristol-Myers Squibb, 2011-2012

OND-003: A multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of low-dose ondansetron for adjunctive therapy in adult patients with obsessive-compulsive disorder who have not adequately responded to treatment with a selective serotonin reuptake inhibitor. Sub-Investigator, Sponsored by Transcept 2011-2012

H8Y-MC-HBDE A Phase 3, Multicenter, Double-Blind Comparison of LY2140023 and Aripiprazole in Patients with DSM-IV-TR Schizophrenia Followed by Open- Label Treatment with LY2140023. Sub-Investigator, sponsored by Eli Lilly and Company, 2011-2013

31-10-270 An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients with Schizophrenia, Sub-Investigator, sponsored by Otsuka, 2010-2013

CX157-201 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects with Treatment Resistant Depression, Sub-Investigator, sponsored by CeNeRx, 2011-2012

WN25305 Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia treated with antipsychotics followed by a 40-week

3/8/18

double-blind, parallelgroup, placebo controlled treatment period. Sub-Investigator, sponsored by Roche, 2011-2012

WN25333 A phase II/III, multi-center, randomized, 4-week, double-blind, parallel group, placebo and active-controlled trial of the safety and efficacy of RO4917838 vs. placebo in patients with an acute exacerbation of schizophrenia. Sub-Investigator, sponsored by Roche, 2011-2012

WN25308 A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics followed by a 28 week, double-blind treatment period. Sub-Investigator, sponsored by Roche, 2011-2012

096-050 Long-Term Eslicarbazepine Acetate Extension Study 093-046 Sub-Investigator, sponsored by Sunovion, 2011-2012

093-046 Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects with Partial Epilepsy Not Well Controlled By Current Antiepileptic Drugs. Sub-Investigator, sponsored by Sunovion, 2011-2012

R092670-SCA-3004 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder; Sub-Investigator, sponsored by OMJSA, 2011-2013

C10953/3074, A 6-Mohth, Open Label, Flexible-Dosage (150 and 200 mg/day)Extension Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated with Bipolar 1 Disorder. Sub-Investigator; Sponsored by Cephalon. 2011-2012

C10953/3071, A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficiency and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major Depression Associated with Bipolar 1 Disorder. Sub-Investigator, Sponsored by Cephalon. 2011-2012

RGH-MD-36 A Long-term open-label study of the safety and tolerability of cariprazine in patients with bipolar 1 disorder. Sub-Investigator, sponsored by Forest, 2011-2012

H8Y-MC-HBBO A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia. Sub-Investigator, sponsored by Eli Lilly and Company, 2011-2013

H8Y-MC-HBBM, A Phase 2, Multi Center, Double Blind Placebo Controlled Study of 2 doses of LY2140023 Vs Placebo in patients with DSM-IV-TR Schizophrenia. Sub-Investigator; sponsored by Eli Lilly and Company, 2011-2012

3/8/18

*REVISED March 2018